Background

According to the World Health Organisation, Helicobacter pylori represents a difficult to manage human pathogen. Classified as a class I carcinogen, bacterial eradiction requires a triple therapy regime consisting of a proton pump inhibitor, amoxicillin and metronidazole or clarithromycin. Unfortunately, antibiotic‑resistant strains of H. pylori have been selected, further hindering therapeutic success.

Novel compounds with antibacterial properties are therefore needed to contrast resistance in H. pylori, while maintaining efficacy towards other bacterial species.

Technology Overview

The present innovation refers to the field of bioeconomy, using biological materials of industrial waste for phytopharmaceutical use. Specifically, the shells of three varieties of chestnut (Castanea sativa) were treated with a hydroalcoholic solution. The extract exhibited an antibacterial activity. The